上机芯片	技术路线	样本编号	正负链信息	基因	参考序列/转录本	核苷酸变化	核苷酸改变-其他形式	突变名称	基因亚区	杂合性	NP号	ENSP号	PubMed	PMID	突变深度	总深度	Readsratio	Ch:por	cpra	Amino_Acids_Length	功能改变	SIFT|Polyphen|MutationTaster	rs号	基因+p（简）	备注	参考文献-解读	突变详情-解读	基因+c.	基因+p.	疾病-报告	参考文献-报告	结果说明-报告	突变类型-报告	引物设计	一键搜索链接	一键搜索链接-学术	Clinvar数据库	filter_0.01	filter_0.05	gnomAD_频率	gnomAD_东亚人_频率	千人频率	千人频率_东亚人	ESP6500	EXAC频率	EXAC_东亚人频率	EXAC_东亚人_纯合频率	EXAC_东亚人_纯合数	遗传性肿瘤正常人频率	遗传性肿瘤正常人频率（50岁以上）	本地频率	本地频率等级	本地纯合频率	check_product	位点筛选-报告	同codon变异check	reads_picture	RepeatTag	VcfFilter	质量是否合格	烈性突变一键筛选	染色体号	开始位置	结束位置	参考基因组碱基	样本检测碱基	是否有修改	是否是库内点	入库时间	同一坐标变异	龙舌兰文献	龙舌兰分级	龙舌兰ACMG等级	MutType	EndExonCheck	GeneExtendCheck	splice_Affect	BGICG_cHGVS	BGICG_pHGVS	BGICG_Function	BGICG_ExIn_ID	BGICG_Trans	ReportGeneCheck	BI_MutType	NewFunction
*	*	yeguiming.yeguiming_Normal	+	BRCA2	NM_000059.3	c.8187G>T	.	p.K2729N	EX18	Hom	NP_000050.2	ENSP00000369497.1	.	8840963	646	661	0.977307	chr13:32937526	chr13-32937526-G-T	3418	Missense	damaging|probably damaging|polymorphism	rs80359065	BRCA2 p.K2729N	1 NM_000059.3(BRCA2):c.8187G>T (p.Lys2729Asn);Variation ID: Help38142Review status: Helpreviewed by expert panel3 stars out of maximum of 4 stars;Clinical significance:Benign;Last evaluated:Aug 10, 2015;Number of submission(s):14Condition(s):;Breast-ovarian cancer, familial 2 [MedGen - OMIM];Fanconi anemia, complementation group D1 [MedGen - Orphanet - OMIM];Fanconi anemia [MedGen - Orphanet - OMIM];Hereditary breast and ovarian cancer syndrome [MeSH - MedGen - Orphanet - OMIM];Hereditary cancer-predisposing syndrome [MedGen];2 ARUP：http://arup.utah.edu/database/BRCA/Variants/BRCA2.php 数据库记录为 1 - Not pathogenic or of no clinical significance。;3 2019/01/10-复核，修改文献2引用格式。	1 Shimelis H, Mesman R L S, Von Nicolai C, et al. BRCA2 hypomorphic missense variants confer moderate risks of breast cancer[J]. Cancer research, 2017.;2 Y?lmaz N K, Karagin P H, Terzi Y K, et al. BRCA1 and BRCA2 sequence variations detected with next-generation sequencing in patients with premature ovarian insufficiency[J]. Journal of the Turkish German Gynecological Association, 2016, 17(2): 77.;3 Fernandes G C, Michelli R A D, Galv?o H C R, et al. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry[J]. Oncotarget, 2016, 7(49): 80465.;4 Hu N, Wang C, Han X Y, et al. Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer[J]. Oncogene, 2004, 23(3): 852.;5 Yoon K A, Park B, Lee B I, et al. Clinically significant unclassified variants in BRCA1 and BRCA2 genes among Korean breast cancer patients[J]. Cancer research and treatment: official journal of Korean Cancer Association, 2017, 49(3): 627.;6 Karchin R, Agarwal M, Sali A, et al. Classifying variants of undetermined significance in BRCA2 with protein likelihood ratios[J]. Cancer informatics, 2008, 6: CIN. S618.;7 Adank M A, Segers H, van Mil S E, et al. Fanconi anemia gene mutations are not involved in sporadic Wilms tumor[J]. Pediatric blood &amp; cancer, 2010, 55(4): 742-744.;8 Akbari M R, Zhang S, Fan I, et al. Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes[J]. Journal of medical genetics, 2011: jmedgenet-2011-100305.;9 Biswas K, Das R, Alter B P, et al. A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay[J]. Blood, 2011: blood-2010-12-324541.;10 Choi M C, Jang J H, Jung S G, et al. Unclassified variants of BRCA1 and BRCA2 in Korean patients with ovarian cancer[J]. International Journal of Gynecological Cancer, 2018, 28(2): 308-315.;11 Eoh K J, Park H S, Park J S, et al. Comparison of clinical outcomes of BRCA1/2 pathologic mutation, variants of unknown significance, or wild type epithelial ovarian cancer patients[J]. Cancer research and treatment: official journal of Korean Cancer Association, 2017, 49(2): 408.;12 Gonzalez-Garay M L, McGuire A L, Pereira S, et al. Personalized genomic disease risk of volunteers[J]. Proceedings of the National Academy of Sciences, 2013: 201315934.;13 Guidugli L, Pankratz V S, Singh N, et al. A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity[J]. Cancer research, 2013, 73(1): 265-275.;14 Guidugli L, Carreira A, Caputo S M, et al. Functional Assays for Analysis of Variants of Uncertain Significance in BRCA 2[J]. Human mutation, 2014, 35(2): 151-164.;[15] Hendriks G, Morolli B, Calléja F M G R, et al. An efficient pipeline for the generation and functional analysis of human BRCA2 variants of uncertain significance[J]. Human mutation, 2014, 35(11): 1382-1391.;16 Hirotsu Y, Nakagomi H, Sakamoto I, et al. Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing[J]. Molecular genetics &amp; genomic medicine, 2015, 3(2): 121-129.;17 Farrugia D J, Agarwal M K, Pankratz V S, et al. Functional assays for classification of BRCA2 variants of uncertain significance[J]. Cancer research, 2008, 68(9): 3523-3531.;18 Lindor N M, Guidugli L, Wang X, et al. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS)[J]. Human mutation, 2012, 33(1): 8-21.;19 Lai K N, Ho W K, Kang I N, et al. Characterization of BRCA1 and BRCA2 variants in multi-ethnic Asian cohort from a Malaysian case-control study[J]. BMC cancer, 2017, 17(1): 149.;20 Zhi X, Szabo C, Chopin S, et al. BRCA1 and BRCA2 sequence variants in Chinese breast cancer families[J]. Human mutation, 2002, 20(6): 474-474.;21 Guidugli L, Shimelis H, Masica D L, et al. Assessment of the clinical relevance of BRCA2 missense variants by functional and computational approaches[J]. The American Journal of Human Genetics, 2018, 102(2): 233-248.;22 Wu X, Wu L, Kong B, et al. The first nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients[J]. International Journal of Gynecological Cancer, 2017, 27(8): 1650-1657.	1 在3例白种人乳腺癌患者和1例白种人对照中以及在164例亚洲乳腺癌患者和128例亚洲对照中检出BRCA2  c.8187G>T  p.Lys2729Asn 突变，文献中表明该突变与亚洲人患乳腺癌的中、低风险相关。;2 对56例卵巢早衰患者和45例健康对照进行研究，在1例卵巢早衰患者和1例健康对照中检出BRCA2 c.8187G>T p.K2729N突变，文献将该突变归为未分类变异。;3 在3例乳腺癌患者的亲属中检出BRCA2 c.8187G>T P.Lys2729Asn突变，HGMD/BIC/LOVD/LOVD IARC/ClinVar/ARUP/BRCA Share?数据库将该突变归为VUS/VUS/probably neutral/class 1/conflicting data/Class 1/VUS ；Polyphen-2/SIFT/Align-GVGD/MAPP/CADD预测结果分别为probably damaging/Predict Not Tolerated/C35/Not tolerated/Low risk；文献认为所有被Clinvar分类为VUS或结果相冲突的变体都被认为是VUSs。;4 对70例食管鳞状细胞癌患者和232例健康对照进行研究，在2例患者和7例对照中检出BRCA2 K2729N突变，作者认为该突变是一种新的多态性。{BP6};5 对328例乳腺癌患者和421例健康对照进行研究，在10例患者和10例对照中检出BRCA2 c.8187G>T p.Lys2729Asn突变，该突变在对照组中的基因型频率大于2％。;6 作者将BRCA2 K2729N 突变归为Uncertain 。详情见正文及附件。;7 作者报道了BRCA2 c.8187G>T p.Lys2729Asn突变。;8 文中指出BRCA2 Lys2729Asn为良性多态性。{BP6};9 在1例急性髓性白血病患者中检出BRCA2基因的p.K2729N/p.S2835X复合杂合突变，通过基于ES细胞的功能检测实验，发现K2729N变异与WT brca2的所有功能检测实验结果一致，作者将其归结为中性变异。{BS3};10 对138例peritoneal, epithelial ovarian, or fallopian tubal (POFT) cancer患者进行研究，在4例患者中检出BRCA2 c.8187G9T p.Lys2729Asn 突变，并将其归为意义未明突变。;11 在4例卵巢癌患者中检出BRCA2 c.8187G>T (p.Lys2729Asn)突变，文献将其归为VUS。;12 在1例乳腺癌患者中检出BRCA2 p.K2729N突变（HGMD文献）。;13 文献报道了BRCA2 K2729N突变，并将其归类为VUS（HGMD文献）。;14 文中提到BRCA2 p.Lys2729Asn突变，将其归类为VUS（HGMD文献）。;[15] 文中提到了BRCA2 p.Lys2729Asn突变，通过功能实验分析，该突变对蛋白质功能的表达导致HAT抗性克隆的数量与野生型hBRCA2的mES细胞表达结果相似，为非致病性变异（HGMD文献）。{BS3};16 报道了6例乳腺癌患者携带BRCA2 c.8187G>T p.K2729N突变，通过两个独立实验室的数据比较显示，该突变为多态性。{BP6};17 文献报道了BRCA2 K2729N突变（文中记录为8415G>T，经ClinVar核对为同一突变），经功能实验分析的方法，多数证据表明该突变为中性突变。{BP6};18 文献报道了BRCA2 c.8187G > T K2729N突变，IARC class为1-非致病突变（HGMD文献，引用文献17）。;19 文献报道了BRCA2 c.8187G>T p.Lys2729Asn突变，PolyPhen-2/SIFT预测分别是Probably damaging/Damaging，文献中表明该突变在未受影响的女性中变异频率> 1％，该突变与乳腺癌风险可能不有关，该突变被数据库分类为非致病性突变。;20 对45例高危乳腺癌患者进行研究，从中检出BRCA2 Lys2729Asn突变（文中记录为8415G>T，经ClinVar核对为同一突变），将该突变归为意义未明突变。;21 作者报道了BRCA2 p.Lys2729Asn c.8187G>T突变，通过同源定向DNA修复(HDR)试验，对BRCA2 DNA结合域的变异进行了全面的功能性分析，表明该突变为良性变异。{BP6};22 对826例卵巢癌患者进行研究，报道了BRCA2 c.8187G>T突变，并将其归为非致病突变（见附件）。{BP6};23 数据库频率>0.01。{BS1};24 ClinVar: Benign。{BP6};25 intervar数据库记录该位点有BS2记录： Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age。{BS2}	BRCA2 c.8187G>T	BRCA2 p.Lys2729Asn	-	*	*	良性多态性	BRCA2;NM_000059.3;c.8187G>T;p.Lys2729Asn|p.K2729N;EX18;CDS17;Hom;ATGCTGTTAA.GCCCAGTTAG;26;661;0.977307;chr13;32937526	https://www.google.com.hk/?gws_rd=ssl#safe=strict&amp;q=BRCA2+(%228187G%3ET%22+%7C+%228187G-%3ET%22+%7C+%228187G--%3ET%22+%7C+%228187G%2FT%22+%7C+%22Lys2729Asn%22+%7C+%22K2729N%22)	https://scholar.google.com.hk/scholar?hl=zh-CN&amp;q=BRCA2+(%228187G%3ET%22+%7C+%228187G-%3ET%22+%7C+%228187G--%3ET%22+%7C+%228187G%2FT%22+%7C+%22Lys2729Asn%22+%7C+%22K2729N%22)	Benign	No	Yes	0.000758	0.009162	0.002596	0.0119		0.000824	0.009711	0	0	0.0	0.0	0.0	A	0.0	:	Yes	No	.	.	PASS	No	No	chr13	32937526	32937526	G	T	*	是	2019-09-05 00:00:00.000	*	无	1	likely benign	snv	N	Nan	N	c.8187G>T	p.K2729N	missense	EX18	NM_000059.3	Yes	snv	missense
*	*	yeguiming.yeguiming_Normal	+	KIT	NM_000222.2	c.2243T>C	.	p.I748T	EX16	Het	NP_000213.1	.	.	.	298	608	0.490132	chr4:55598046	chr4-55598046-T-C	976	Missense	tolerated|benign|polymorphism	rs572852980	KIT p.I748T	*	[1] Wang Y Y, Zhou G B, Yin T, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102(4):1104-1109.;2 Ashman L K, Griffith R. Therapeutic targeting of c-KIT in cancer.[J]. Expert Opinion on Investigational Drugs, 2013, 22(1):103.;3 Tinsley, S. P. To establish the role of mutations in c-KIT tyrosine kinase in the pathogenesis and therapy of core-binding factor-related acute myeloid leukaemia (AML)[J]. University College London, 2014.;4 Reikvam H, Hatfield K J, Kittang A O, et al. Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications[J]. Journal of Biomedicine &amp; Biotechnology, 2011, 2011(2):104631.;5 Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation.[J]. Applied Immunohistochemistry &amp; Molecular Morphology, 2005, 13(3):205.	[1] 在白血病患者中检出该突变。;2 该突变位于KINASE INSERT;3 在白血病患者中检出该突变。;4 提及该突变。;5 在白血病患者中检出该突变。	KIT c.2243T>C	KIT p.Ile748Thr	-	[1] Wang Y Y, Zhou G B, Yin T, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102(4):1104-1109.	在受检者的KIT基因中检测出错义突变c.2243T>C（p.Ile748Thr，Het），该突变导致其所在基因编码蛋白第748位氨基酸由突变为苏氨酸。 在白血病患者中检出该突变[1]。其在千人基因组中的频率为0。利用Mutation taster，Polyphen-2及SIFT对其进行蛋白功能预测，预测结果分别为tolerated，benign，polymorphism。综上分析，该突变是一个意义未明突变-1，现有的科学研究尚不能明确其与相关肿瘤发生风险的关系。	意义未明突变	KIT;NM_000222.2;c.2243T>C;p.Ile748Thr|p.I748T;EX16;CDS16;Het;GGCTCATACA.AGAAAGAGAT;21;608;0.490132;chr4;55598046	https://www.google.com.hk/?gws_rd=ssl#safe=strict&amp;q=KIT+(%222243T%3EC%22+%7C+%222243T-%3EC%22+%7C+%222243T--%3EC%22+%7C+%222243T%2FC%22+%7C+%22Ile748Thr%22+%7C+%22I748T%22)	https://scholar.google.com.hk/scholar?hl=zh-CN&amp;q=KIT+(%222243T%3EC%22+%7C+%222243T-%3EC%22+%7C+%222243T--%3EC%22+%7C+%222243T%2FC%22+%7C+%22Ile748Thr%22+%7C+%22I748T%22)	Uncertain_significance	Yes	Yes	8e-06	0.000116	0.0002	0.001		8e-06	0.000116	0	0	0.0004			A		:	Yes	No	.	.	PASS	Yes	No	chr4	55598046	55598046	T	C	*	是	2019/1月数据库复核	*	[1] Wang Y Y, Zhou G B, Yin T, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102(4):1104-1109.	3		snv	N	Nan	N	c.2243T>C	p.I748T	missense	EX16	NM_000222.2	Yes	snv	missense
